Zim

ZIM Corp. engages in the development and sale of enterprise database software. The company is headquartered in Ottawa, Ontario. The company went IPO on 2003-10-16. Through its subsidiary, NuvoBio Corporation, the Company is involved in research and development projects for cancer therapeutics. The firm is developing intellectual property and advancing research and development in the areas of new synthetic drugs and immunotherapies. The firm is funding research and development projects in areas, including implementing unique molecular interaction and analytics using supercomputing technologies to design small peptide drugs that bind to target proteins for cancer therapies and the development of bi-specific immunology therapies for the treatment of kidney cancer. The company is also funding research and development projects in the areas of new peptide-derived inhibitors for therapeutic intervention against various cancer cell lines in the presence or absence of chemo therapeutics to characterize the in vivo effects of promising inhibitors.